Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $7.99

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $7.99, but opened at $7.79. Ocular Therapeutix shares last traded at $7.93, with a volume of 164,229 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Ocular Therapeutix in a report on Wednesday, February 14th. JMP Securities restated a "market outperform" rating and issued a $24.00 target price on shares of Ocular Therapeutix in a report on Wednesday, March 13th. Bank of America assumed coverage on Ocular Therapeutix in a report on Friday, February 9th. They issued a "buy" rating and a $15.00 target price for the company. Piper Sandler upped their price target on Ocular Therapeutix from $10.00 to $15.00 and gave the stock an "overweight" rating in a report on Monday, February 26th. Finally, StockNews.com lowered Ocular Therapeutix from a "hold" rating to a "sell" rating in a report on Friday, April 5th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.80.

Ocular Therapeutix Trading Down 2.4 %

The firm has a market capitalization of $1.16 billion, a P/E ratio of -6.24 and a beta of 1.31. The company has a quick ratio of 6.59, a current ratio of 6.66 and a debt-to-equity ratio of 0.82. The business has a 50-day moving average price of $8.63 and a 200-day moving average price of $5.25.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.28). Ocular Therapeutix had a negative return on equity of 321.12% and a negative net margin of 138.15%. The business had revenue of $14.80 million for the quarter, compared to analysts' expectations of $15.31 million. Analysts anticipate that Ocular Therapeutix, Inc. will post -0.68 earnings per share for the current year.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, CEO Antony C. Mattessich sold 18,338 shares of the company's stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total value of $90,773.10. Following the sale, the chief executive officer now directly owns 427,943 shares in the company, valued at $2,118,317.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ocular Therapeutix news, major shareholder Summer Road Llc bought 930,851 shares of the firm's stock in a transaction dated Monday, February 26th. The shares were bought at an average price of $7.52 per share, for a total transaction of $6,999,999.52. Following the completion of the acquisition, the insider now owns 8,591,401 shares of the company's stock, valued at $64,607,335.52. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Antony C. Mattessich sold 18,338 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total value of $90,773.10. Following the sale, the chief executive officer now owns 427,943 shares in the company, valued at approximately $2,118,317.85. The disclosure for this sale can be found here. Insiders have sold 39,366 shares of company stock worth $194,862 over the last three months. Company insiders own 5.50% of the company's stock.

Institutional Trading of Ocular Therapeutix

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Ocular Therapeutix by 26.0% during the fourth quarter. Vanguard Group Inc. now owns 5,118,102 shares of the biopharmaceutical company's stock worth $22,827,000 after purchasing an additional 1,057,123 shares during the last quarter. Trust Co. of Vermont lifted its stake in shares of Ocular Therapeutix by 20.0% during the fourth quarter. Trust Co. of Vermont now owns 6,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,000 shares during the period. Virtu Financial LLC acquired a new position in shares of Ocular Therapeutix during the fourth quarter valued at $277,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Ocular Therapeutix by 31.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 53,344 shares of the biopharmaceutical company's stock valued at $238,000 after acquiring an additional 12,859 shares during the period. Finally, GSA Capital Partners LLP lifted its stake in shares of Ocular Therapeutix by 5.7% during the fourth quarter. GSA Capital Partners LLP now owns 246,903 shares of the biopharmaceutical company's stock valued at $1,101,000 after acquiring an additional 13,321 shares during the period. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.